(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Metastatic Breast Cancer pipeline constitutes key companies continuously working towards developing Metastatic Breast Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
“Metastatic Breast Cancer Pipeline Insight, 2023″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Metastatic Breast Cancer Market.
The Metastatic Breast Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Metastatic Breast Cancer Pipeline Report:
- Companies across the globe are diligently working toward developing novel Metastatic Breast Cancer treatment therapies with a considerable amount of success over the years.
- Metastatic Breast Cancer companies working in the treatment market are Menarini Group, Phoenix Molecular Designs, Dantari, Inc., AstraZeneca, Orion Pharma, Tyme, Inc. Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Shanghai Miracogen Inc., Syncore Biotechnology, Byondis, RemeGen, and others, are developing therapies for the Metastatic Breast Cancer treatment
- Emerging Metastatic Breast Cancer therapies such as – MEN1611, PMD-026, DAN-222, AZD 8205, ODM-209, SM-88, KN026, MRG002, SB 05, Trastuzumab duocarmazine, Disitamab (RC48)Vedotin, and others are expected to have a significant impact on the Metastatic Breast Cancer market in the coming years.
- In September 2021, Seagen Inc. announced that the two companies have entered into an exclusive worldwide licensing agreement to develop and commercialize disitamab vedotin, a novel HER2-targeted ADC
- On May 04, 2022, At the ESMO Breast Cancer Meeting, which will be held in Berlin, Germany from May 3-5, 2022, Rhizen Pharmaceuticals AG announced that it would present encouraging interim data from a Ph2 trial of Tenalisib that is currently being conducted in patients with locally advanced or metastatic breast cancer. In patients with primary and secondary resistant mBC, tenalisib was well tolerated and showed good preliminary efficacy as a single drug. Results encourage future development of tenalisib in patients with HR+ and HER2- MBC.
- In April 2022, Data from the phase II clinical research of the chemo-free regimen of KN026 in combination with KN046 (KN026-203), according to an announcement from Alphamab Oncology, were presented as an E-poster at the AACR Annual Conference 2022. (AACR 2022). Twenty patients were evaluable for overall response as of August 10, 2021, with ORRs of 55.0%, DCRs of 85.0%, and 6-month PFS rates of 84.1% for those with HER2-positive solid tumours other than breast or gastric cancer. Of the 11 CRC patients who were evaluable, ORR and DCR were 45.5% and 90.9%, respectively.
- In April 2022, The I-SPY 2.2 TRIAL for the treatment of HER2-positive breast cancer in the neoadjuvant setting has chosen Ambrx Biopharma Inc.’s antibody-drug conjugate (ADC) ARX788 as a new experimental treatment arm, according to Quantum Leap Healthcare CollaborativeTM (Quantum Leap) and Ambrx Biopharma Inc. The I-SPY 2.2 TRIAL, sponsored by Quantum Leap, is a follow-up to the I-SPY 2 TRIAL and aims to develop tailored treatments by customizing therapy for each patient to improve the clinical outcome
- In March 2022, Researchers from Georgetown University submitted the poster presentation SM-88, D/L-alpha-metyrosine, is a new anti-cancer drug in oestrogen receptor-positive breast cancer, which was made available by TYME Technologies, Inc. In 2022, the American Association for Cancer Research (AACR) Annual Conference was held in New Orleans, Louisiana, and the abstract was presented there. In September 2021, TYME Technologies, Inc. announced that the first patient had been dosed in the Georgetown University-led Phase II OASIS trial (NCT04720664) being conducted at several MedStar Health hospitals in patients with metastatic HR+/HER2-breast cancer who had previously received a CDK4/6 inhibitor regimen. Georgetown’s academic clinical partner is MedStar Health
- In February 2022, In their Phase 1b monotherapy clinical trial, Phoenix Molecular Designs (PhoenixMD) reported the end of patient enrollment and PMD-026 treatment. PhoenixMD has advanced PMD-026 into Phase 2 combo trials for triple-negative breast cancer (TNBC) and hormone-positive breast cancer after the successful completion of patient enrolment in this Phase 1/1b trial
Metastatic Breast Cancer Overview
Metastatic Breast Cancer also called stage IV – is breast cancer that has spread to another part of the body, most commonly thebones, lungs, brain, or liver.
Get a Free Sample PDF Report to know more about Metastatic Breast Cancer Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/metastatic-breast-cancer-pipeline-insight?utm_source=Medgadget&utm_medium=pressrelease&utm_campaign=gpr
Emerging Metastatic Breast Cancer Drugs Under Different Phases of Clinical Development Include:
- MEN1611: Menarini Group
- PMD-026: Phoenix Molecular Designs
- DAN-222: Dantari, Inc.
- Giredestrant: Roche
- AZD 8205: AstraZeneca
- Disitamab Vedotin: RemeGen
- ODM-209: Orion Pharma
- EndoTAG®-1 (SB05): SynCore Biotechnology
- Stenoparib (2X-121): Allarity Therapeutics
- SM-88: Tyme, Inc
- KN026: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- MRG002: Shanghai Miracogen Inc
- SB 05: Syncore Biotechnology
- Trastuzumab duocarmazine: Byondis
- Disitamab (RC48)Vedotin: RemeGen
Route of Administration
Metastatic Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
Molecule Type
Products have been categorized under various Molecule types, such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Metastatic Breast Cancer Pipeline Therapeutics Assessment
- Metastatic Breast Cancer Assessment by Product Type
- Metastatic Breast Cancer By Stage and Product Type
- Metastatic Breast Cancer Assessment by Route of Administration
- Metastatic Breast Cancer By Stage and Route of Administration
- Metastatic Breast Cancer Assessment by Molecule Type
- Metastatic Breast Cancer by Stage and Molecule Type
DelveInsight’s Metastatic Breast Cancer Report covers around products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Metastatic Breast Cancer product details are provided in the report. Download the Metastatic Breast Cancer pipeline report to learn more about the emerging Metastatic Breast Cancer therapies at:
Some of the key companies in the Metastatic Breast Cancer Therapeutics Market include:
Key companies developing therapies for Metastatic Breast Cancer are – RemeGen, SynCore Biotechnology, Allarity Therapeutics, Daiichi Sankyo Company, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Byondis B.V., Jiangsu Hansoh Pharmaceutical Co., Ltd., Shanghai Miracogen Inc., Ambrx, Inc., Daehwa Pharmaceutical Co., Ltd., Phoenix Molecular Designs, Menarini Group, Samus Therapeutics, Inc., Hanmi Pharmaceutical Company Limited, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Immutep Limited, Arvinas Inc., G1 Therapeutics, Mirati Therapeutics Inc., Chia Tai Tianqing Pharmaceutical, Shanghai Pharmaceuticals Holding Co., Ltd, Pfizer, OncoTherapy Science, Inc., Eisai Inc., Dizal Pharmaceuticals, Tyme, Inc, Orion Pharma, HiberCell, Inc., Rhizen Pharmaceuticals SA, Hutchison Medipharma Limited, OncoPep Inc., Taizhou Hanzhong biomedical co. LTD, Kind Pharmaceuticals LLC, Dantari, Inc., Veru Inc., Taiho Oncology, Eli Lilly and Company, Sermonix Pharmaceuticals, Merus N.V., Minerva Biotechnologies Corporation, Kintara Therapeutics, Inc., Sichuan Baili Pharmaceutical Co., Ltd., Regor Pharmaceuticals Inc., Tianjin Hemay Biotech, Jiangsu Simcere Pharmaceutical Co., Ltd., and others.
Metastatic Breast Cancer Pipeline Analysis:
The Metastatic Breast Cancer pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Metastatic Breast Cancer with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Breast Cancer Treatment.
- Metastatic Breast Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Metastatic Breast Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Metastatic Breast Cancer market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Metastatic Breast Cancer drugs and therapies- https://www.delveinsight.com/sample-request/metastatic-breast-cancer-pipeline-insight?utm_source=Medgadget&utm_medium=pressrelease&utm_campaign=gpr
Metastatic Breast Cancer Pipeline Market Drivers
- Increasing prevalence of breast cancer, increasing investments in R&D, launch of several diagnostic and screening programs are some of the important factors that are fueling the Metastatic Breast Cancer Market.
Metastatic Breast Cancer Pipeline Market Barriers
- However, high cost associated with the treatment, several side effects associated with the use of breast cancer therapeutics and other factors are creating obstacles in the Metastatic Breast Cancer Market growth.
Scope of Metastatic Breast Cancer Pipeline Drug Insight
- Coverage: Global
- Key Metastatic Breast Cancer Companies: Menarini Group, Phoenix Molecular Designs, Dantari, Inc., AstraZeneca, Orion Pharma, Tyme, Inc. Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Shanghai Miracogen Inc., Syncore Biotechnology, Byondis, RemeGen, and others
- Key Metastatic Breast Cancer Therapies: MEN1611, PMD-026, DAN-222, AZD 8205, ODM-209, SM-88, KN026, MRG002, SB 05, Trastuzumab duocarmazine, Disitamab (RC48)Vedotin, and others
- Metastatic Breast Cancer Therapeutic Assessment: Metastatic Breast Cancer current marketed and Metastatic Breast Cancer emerging therapies
- Metastatic Breast Cancer Market Dynamics: Metastatic Breast Cancer market drivers and Metastatic Breast Cancer market barriers
Request for Sample PDF Report for Metastatic Breast Cancer Pipeline Assessment and clinical trials-
Table of Contents
| 1 | Metastatic Breast Cancer Report Introduction |
| 2 | Metastatic Breast Cancer Executive Summary |
| 3 | Metastatic Breast Cancer Overview |
| 4 | Metastatic Breast Cancer- Analytical Perspective In-depth Commercial Assessment |
| 5 | Metastatic Breast Cancer Pipeline Therapeutics |
| 6 | Metastatic Breast Cancer Late Stage Products (Phase II/III) |
| 7 | Metastatic Breast Cancer Mid Stage Products (Phase II) |
| 8 | Metastatic Breast Cancer Early Stage Products (Phase I) |
| 9 | Metastatic Breast Cancer Preclinical Stage Products |
| 10 | Metastatic Breast Cancer Therapeutics Assessment |
| 11 | Metastatic Breast Cancer Inactive Products |
| 12 | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13 | Metastatic Breast Cancer Key Companies |
| 14 | Metastatic Breast Cancer Key Products |
| 15 | Metastatic Breast Cancer Unmet Needs |
| 16 | Metastatic Breast Cancer Market Drivers and Barriers |
| 17 | Metastatic Breast Cancer Future Perspectives and Conclusion |
| 18 | Metastatic Breast Cancer Analyst Views |
| 19 | Appendix |
| 20 | About DelveInsight |
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Latest Reports:
DelveInsight’s “Hypertrophic Scar Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Hypertrophic Scar, historical and forecasted epidemiology as well as the Hypertrophic Scar market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
DelveInsight’s “Lung Fibrosis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Lung Fibrosis, historical and forecasted epidemiology as well as the Lung Fibrosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
DelveInsight’s “Anterior Uveitis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Anterior Uveitis, historical and forecasted epidemiology as well as the Anterior Uveitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
22q11.2 deletion syndrome Market
DelveInsight’s “22q11.2 Deletion Syndrome Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the 22q11.2 Deletion Syndrome, historical and forecasted epidemiology as well as the 22q11.2 Deletion Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
X-Linked Retinitis Pigmentosa (XLRP) Market
DelveInsight’s “X-Linked Retinitis Pigmentosa Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the X-Linked Retinitis Pigmentosa (XLRP), historical and forecasted epidemiology as well as the X-Linked Retinitis Pigmentosa market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
DelveInsight’s “Scedosporium Infection Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Scedosporium Infection, historical and forecasted epidemiology as well as the Scedosporium Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2027 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2027 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.
Vein Illumination Devices Market
DelveInsight’s “Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2027” report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.
DelveInsight’s “Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2027” report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.
Latest Reports By DelveInsight
Hypertrophic Scar Market | Lung Fibrosis Market | Anterior Uveitis Market | 22q11.2 deletion syndrome Market | X-Linked Retinitis Pigmentosa (XLRP) Market | Acute Radiation Syndrome Market | Alpha-1 Protease Inhibitor Deficiency Market | Androgenetic Alopecia Market | Hyperlipidemia Market | Cardiotoxicity Market | Hypertrophic Cardiomyopathy Market | Fatty Acid Oxidation Disorders (FAODs) Market | Androgen Insensitivity Syndrome Market | Emphysema Market | Canaloplasty Market | Dravet Syndrome Market | Celiac Disease Market | Chlamydia Infections Market | Syphilis Market | Renal Tubular Acidosis Market | Palmoplantar Pustulosis (PPP) Market | Aplastic Anemia Market | Bacterial Pneumonia Market | B cell Chronic Lymphocytic Leukemia Market | B cell Lymphomas Market | Behcets Disease Market Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast—by 2035 | Glioblastoma Market
Trending Reports:
- Menorrhalgia Market
- Complicated Intra-Abdominal Infections market
- Bronchial Spasm Market
- Acute Radiation Syndrome Market
- Age Related Vision Dysfunction Market
- Cerebral Aneurysm Market
To know more about our Consulting Services, Click here: DelveInsight Healthcare Consulting
Recent Blog’s By DelveInsight:
- Insights Into The Cutaneous T-cell Lymphoma Treatment Market
- Roche’s HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
- Emerging Role of Digital Health in the Field of Oncology
- How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
- How are Technological Trends and Innovations Reshaping the Dementia Care
- Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
- Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
- Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
- Evaluating the Key Trends and Technologies Shaping the Future of Dentistry
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187